Talphera Inc. (TLPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Talphera Inc. (TLPH) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.44 Million) by net assets ($17.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Talphera Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Talphera Inc. - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Talphera Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Talphera Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Talphera Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
POLARIS WORKS Inc
KQ:123010
|
0.019x |
|
MODULIGHT OY EO 1
F:78W
|
0.019x |
|
Beshom Holdings Bhd
KLSE:7668
|
0.033x |
|
Avax One Technology Ltd.
NASDAQ:AVX
|
-0.048x |
|
PENTIXAPHARM HOLDING N AG
XETRA:PTP
|
N/A |
|
Defense Metals Corp
V:DEFN
|
-0.024x |
|
KPM TECH Co. Ltd
KQ:042040
|
0.241x |
|
DSR Corp
KO:155660
|
0.038x |
Annual Cash Flow Conversion Efficiency for Talphera Inc. (2008–2025)
The table below shows the annual cash flow conversion efficiency of Talphera Inc. from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Talphera Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.04 Million | $-11.36 Million | -0.667x | +57.92% |
| 2024-12-31 | $8.00 Million | $-12.68 Million | -1.585x | -27.82% |
| 2023-12-31 | $14.11 Million | $-17.49 Million | -1.240x | +4.51% |
| 2022-12-31 | $21.81 Million | $-28.33 Million | -1.299x | -255.38% |
| 2021-12-31 | $-35.89 Million | $-30.00 Million | 0.836x | +21.02% |
| 2020-12-31 | $-55.75 Million | $-38.51 Million | 0.691x | -44.11% |
| 2019-12-31 | $-41.42 Million | $-51.18 Million | 1.236x | +118.08% |
| 2018-12-31 | $4.25 Million | $-29.07 Million | -6.836x | -938.53% |
| 2017-12-31 | $-36.51 Million | $-29.77 Million | 0.815x | -85.20% |
| 2016-12-31 | $-5.34 Million | $-29.39 Million | 5.508x | +1014.04% |
| 2015-12-31 | $33.11 Million | $-19.95 Million | -0.603x | +18.41% |
| 2014-12-31 | $46.66 Million | $-34.46 Million | -0.739x | -10994.20% |
| 2013-12-31 | $73.16 Million | $-487.00K | -0.007x | +99.08% |
| 2012-12-31 | $33.85 Million | $-24.58 Million | -0.726x | +17.01% |
| 2011-12-31 | $17.47 Million | $-15.29 Million | -0.875x | -571.70% |
| 2010-12-31 | $-65.89 Million | $-12.22 Million | 0.186x | -49.37% |
| 2009-12-31 | $-52.99 Million | $-19.42 Million | 0.366x | -35.38% |
| 2008-12-31 | $-33.34 Million | $-18.90 Million | 0.567x | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more